A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26
Last updated 2026-05-22
Summary
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
Conditions
Interventions
- DRUG
-
VX-522 mRNA therapy
Oral inhalation using nebulizer.
- DRUG
-
IVA
Tablet for oral administration.
Sponsors & Collaborators
- collaborator UNKNOWN
-
Vertex Pharmaceuticals Incorporated
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-02-27
- Primary Completion
- 2026-04-21
- Completion
- 2026-09-09
- FDA Drug
- Yes
Countries
- United States
- Australia
- Belgium
- Canada
- Germany
- Sweden
- United Kingdom
Study Locations
More Related Trials
-
A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
NCT02709109 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
NCT02508207 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
NCT03912233 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
NCT00457821 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
NCT02392234 ·Status: COMPLETED ·Phase: PHASE3
-
Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
NCT03768089 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
NCT03911713 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
NCT01262352 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation
NCT02565914 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
NCT03224351 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
NCT00909727 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
NCT00909532 ·Status: COMPLETED ·Phase: PHASE3
-
Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
NCT00865904 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
NCT00953706 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
NCT05076149 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
NCT05422222 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
NCT03029455 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
NCT02725567 ·Status: COMPLETED ·Phase: PHASE3
-
Rollover Study of VX-770 in Cystic Fibrosis Subjects
NCT01117012 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
NCT02951182 ·Status: COMPLETED ·Phase: PHASE2
-
Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
NCT01225211 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
NCT03447262 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT03447249 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT03525444 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor
NCT02412111 ·Status: COMPLETED ·Phase: PHASE3